While peptide protocols are similar in principle, cervical applications should only be pursued under direct medical supervision
I am a physician in physical medicine and rehabilitation who spends a lot of time thinking about how people recover from musculoskeletal injuries, including tendon problems, ligament sprains, muscle strains and joint injuries
Extrapolating a continuous, high-dose copper-complex therapy without this data is hazardous due to the risk of copper accumulation
No human trial has shown that MOTS-c prevents muscle loss during retatrutide use
Oral wins on convenience and lack of injection risk but has the weakest bioavailability rationale for a peptide of this size
GLOW is typically a mixture of BPC-157, TB-500 and GHK-Cu, for example as a 70 mg blend, and therefore has no dedicated anti-inflammatory NF-kB axis